HIV/SIV (simian immunodeficiency virus) infection leads to a loss of CD4+ T helper (Th) cells in number and function that begins during the acute phase and persists through the chronic phase of infection. In particular, there is a drastic decrease of Th17 and Th22 cells in the HIV/SIV-infected gastrointestinal (GI) tract as a source of interleukin (IL)-17 and IL-22. These cytokines are vital in the immune response to extracellular pathogens and maintenance of the GI tract. However, innate lymphoid cells (ILCs) are a source of IL-17 and IL-22 during the early stages of an immune response in mucosal tissue and remain vital cytokine producers when the immune response is persistent. Here, we wanted to determine whether ILCs are a source of IL-17 and IL-22 in the SIV-infected colon and could compensate for the loss of Th17 and Th22 cells. As a control, we evaluated the frequency and number of ILCs expressing interferon-gamma (IFNγ) and tumor necrosis factor-alpha (TNFα). We determined the frequency and number of cytokine expressing ILC subsets and T cell subsets within leukocytes from the colons of uninfected as well as acute and chronic SIV-infected colons without in vitro mitogenic stimulation. In the present study, we find that: (1) the frequency of IL-22, IFNγ, and TNFα but not IL-17 producing ILCs is increased in the acutely infected colon and remains high during the chronically infected colon relative to cytokine expressing ILCs in the uninfected colon, (2) ILCs are a significant source of IL-22, IFNγ, and TNFα but not IL-17 when CD4+ T lymphocytes in the gut lose their capacity to secrete these cytokines during SIV infection, and (3) the changes in the cytokines expressed by ILCs relative to CD4+ T cells in the infected colon were not due to increases in the frequency or number of ILCs in relation to T lymphocytes found in the tissue.
Get full access to this article
View all access options for this article.
References
1.
VeazeyRS, DeMariaM, ChalifouxLV, et al.: Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science, 1998; 280:427–431.
2.
BrenchleyJM, SchackerTW, RuffLE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med, 2004; 200:749–759.
3.
KaderM, WangX, PiatakM, et al.: Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol, 2009; 2:439–449.
4.
LeungJM, DavenportM, WolffMJ, et al.: IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol, 2014; 7:124–133.
5.
BarouchDH, GhneimK, BoscheWJ, et al.: Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys. Cell, 2016; 165:656–667.
6.
KlattNR, EstesJD, SunX, et al.: Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol, 2012; 5:646–657.
7.
ZhengY, ValdezPA, DanilenkoDM, et al.: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med, 2008; 14:282–289.
TrifariS, KaplanCD, TranEH, CrellinNK, SpitsH: Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol, 2009; 10:864–871.
10.
BasuR, O'Quinn DarrellB, Silberger DanielJ, et al.: Th22 cells are an important source of IL-22 for host protection against enteropathogenic bacteria. Immunity, 2012; 37:1061–1075.
11.
KimCJ, NazliA, RojasOL, et al.: A role for mucosal IL-22 production and Th22 cells in HIV-associated mucosal immunopathogenesis. Mucosal Immunol, 2012; 5:670–680.
12.
XuH, WangX, VeazeyRS: Th17 cells coordinate with Th22 cells in maintaining homeostasis of intestinal tissues and both are depleted in SIV-infected macaques. J AIDS Clin Res, 2014; 5:302.
13.
ZhaJM, LiHS, LinQ, et al.: Interleukin 22 expands transit-amplifying cells while depleting Lgr5(+) stem cells via inhibition of Wnt and notch signaling. Cell Mol Gastroenterol Hepatol, 2019; 7:255–274.
14.
EstesJD, HarrisLD, KlattNR, et al.: Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog, 2010; 6:e1001052.
15.
SomsoukM, EstesJD, DeleageC, et al.: Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS, 2015; 29:43–51.
16.
YeP, RodriguezFH, KanalyS, et al.: Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med, 2001; 194:519–527.
17.
MarchiandoAM, ShenL, GrahamWV, et al.: The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology, 2011; 140:1208–1218 e1201–e1202.
18.
SasakiN, SachsN, WiebrandsK, et al.: Reg4+ deep crypt secretory cells function as epithelial niche for Lgr5+ stem cells in colon. Proc Natl Acad Sci U S A, 2016; 113:E5399–E5407.
19.
GaudinoSJ, BeaupreM, LinX, et al..: IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunity. Mucosal Immunol 2020.
20.
KumarP, MoninL, CastilloP, et al.: Intestinal interleukin-17 receptor signaling mediates reciprocal control of the Gut microbiota and autoimmune inflammation. Immunity, 2016; 44:659–671.
21.
LiangSC, TanXY, LuxenbergDP, et al.: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med, 2006; 203:2271–2279.
22.
ZaragozaMM, Sankaran-WaltersS, CanfieldDR, et al.: Persistence of gut mucosal innate immune defenses by enteric alpha-defensin expression in the simian immunodeficiency virus model of AIDS. J Immunol, 2011; 186:1589–1597.
23.
ArtisD, SpitsH: The biology of innate lymphoid cells. Nature, 2015; 517:293–301.
24.
EberlG, ColonnaM, Di SantoJP, McKenzieAN: Innate lymphoid cells. Innate lymphoid cells: A new paradigm in immunology. Science, 2015; 348:aaa6566.
25.
CastlemanMJ, DillonSM, PurbaCM, et al.: Commensal and pathogenic bacteria indirectly induce IL-22 but not IFNgamma production from human colonic ILC3s via multiple mechanisms. Front Immunol, 2019; 10:649.
26.
CastlemanMJ, DillonSM, PurbaC, et al.: Enteric bacteria induce IFNgamma and Granzyme B from human colonic Group 1 Innate Lymphoid Cells. Gut Microbes, 2020; 12:1667723.
27.
SpitsH, ArtisD, ColonnaM, et al.: Innate lymphoid cells—A proposal for uniform nomenclature. Nat Rev Immunol, 2013; 13:145–149.
28.
FuchsA, VermiW, LeeJS, et al.: Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity, 2013; 38:769–781.
29.
MoroK, YamadaT, TanabeM, et al.: Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature, 2010; 463:540–544.
30.
MjosbergJ, BerninkJ, GolebskiK, et al.: The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity, 2012; 37:649–659.
31.
CellaM, FuchsA, VermiW, et al.: A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature, 2009; 457:722–725.
32.
CellaM, OteroK, ColonnaM: Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc Natl Acad Sci U S A, 2010; 107:10961–10966.
33.
BerninkJH, KrabbendamL, GermarK, et al.: Interleukin-12 and -23 control plasticity of CD127(+) group 1 and group 3 innate lymphoid cells in the intestinal lamina propria. Immunity, 2015; 43:146–160.
34.
BerninkJH, PetersCP, MunnekeM, et al.: Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol, 2013; 14:221–229.
35.
RaykovaA, CarregaP, LehmannFM, et al.: Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells. Blood Adv, 2017; 1:2679–2691.
36.
KrabbendamL, HeestersBA, KradolferCMA, SpitsH, BerninkJH: Identification of human cytotoxic ILC3s. Eur J Immunol 2020.
37.
BalSM, BerninkJH, NagasawaM, et al.: IL-1beta, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol, 2016; 17:636–645.
38.
CogswellA, FergusonN, BarkerE: Presence of inflammatory group I and III innate lymphoid cells in the colon of simian immunodeficiency virus-infected rhesus macaques. J Virol, 2020; 94:e01914-19.
39.
KumarP, ThakarMS, OuyangW, MalarkannanS: IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol, 2013; 6:69–82.
40.
XuH, WangX, LiuDX, Moroney-RasmussenT, LacknerAA, VeazeyRS: IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol, 2012; 5:658–669.
41.
CellaM, GaminiR, SeccaC, et al.: Subsets of ILC3-ILC1-like cells generate a diversity spectrum of innate lymphoid cells in human mucosal tissues. Nat Immunol, 2019; 20:980–991.
42.
LiH, Richert-SpuhlerLE, EvansTI, et al.: Hypercytotoxicity and rapid loss of NKp44+ innate lymphoid cells during acute SIV infection. PLoS Pathog, 2014; 10:e1004551.
43.
XuH, WangX, LacknerAA, VeazeyRS: Type 3 innate lymphoid cell depletion is mediated by TLRs in lymphoid tissues of simian immunodeficiency virus-infected macaques. FASEB J, 2015; 29:5072–5080.
44.
WangY, LifshitzL, GellatlyK, et al.: HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand TCF7-dependent memory NK cells. Nat Immunol. Mar, 2020; 21:274–286.
45.
GlatzerT, KilligM, MeisigJ, et al.: RORgammat(+) innate lymphoid cells acquire a proinflammatory program upon engagement of the activating receptor NKp44. Immunity, 2013; 38:1223–1235.
46.
PrezaGC, YangOO, ElliottJ, AntonPA, OchoaMT: T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. PLoS One, 2015; 10:e0122723.
47.
RonnLC, HartzBP, BockE: The neural cell adhesion molecule (NCAM) in development and plasticity of the nervous system. Exp Gerontol, 1998; 33:853–864.
48.
RamDR, ManickamC, HueberB, et al.: Tracking KLRC2 (NKG2C)+ memory-like NK cells in SIV+ and rhCMV+ rhesus macaques. PLoS Pathog, 2018; 14:e1007104.
49.
WeisgrauKL, RiesM, PomplunN, EvansDT, RakaszEG: OMIP-035: Functional analysis of natural killer cell subsets in macaques. Cytometry A, 2016; 89:799–802.
50.
MjosbergJM, TrifariS, CrellinNK, et al.: Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol, 2011; 12:1055–1062.
51.
PriceAE, LiangHE, SullivanBM, et al.: Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A, 2010; 107:11489–11494.
52.
KloverprisHN, KazerSW, MjosbergJ, et al.: Innate lymphoid cells are depleted irreversibly during acute HIV-1 infection in the absence of viral suppression. Immunity, 2016; 44:391–405.
53.
ReevesRK, RajakumarPA, EvansTI, et al.: Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. Blood, 2011; 118:3321–3330.
54.
PhamTA, ClareS, GouldingD, et al.: Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe, 2014; 16:504–516.
55.
AndohA, ZhangZ, InatomiO, et al.: Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology, 2005; 129:969–984.
56.
LejeuneD, DumoutierL, ConstantinescuS, KruijerW, SchuringaJJ, RenauldJC: Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem, 2002; 277:33676–33682.
57.
WalkerEM, SlisarenkoN, GerretsGL, et al.: Dysregulation of IL-17/IL-22 effector functions in blood and gut mucosal gamma delta T cells correlates with increase in circulating leaky gut and inflammatory markers during cART-treated chronic SIV infection in macaques. Front Immunol, 2021; 12:647398.
StaceyAR, NorrisPJ, QinL, et al.: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol, 2009; 83:3719–3733.
60.
WatanabeD, UehiraT, YonemotoH, et al.: Sustained high levels of serum interferon-gamma during HIV-1 infection: A specific trend different from other cytokines. Viral Immunol, 2010; 23:619–625.
61.
AbelK, RockeDM, ChohanB, FrittsL, MillerCJ: Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol, 2005; 79:12164–12172.
62.
SchroderK, HertzogPJ, RavasiT, HumeDA: Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol, 2004; 75:163–189.
63.
KakG, RazaM, TiwariBK: Interferon-gamma (IFN-gamma): Exploring its implications in infectious diseases. Biomol Concepts, 2018; 9:64–79.
64.
ItoR, Shin-YaM, KishidaT, et al.: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol, 2006; 146:330–338.
65.
RefaeliY, Van ParijsL, AlexanderSI, AbbasAK: Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med, 2002; 196:999–1005.
66.
KleinSL, FlanaganKL: Sex differences in immune responses. Nat Rev Immunol, 2016; 16:626–638.
67.
WangF, SchwarzBT, GrahamWV, et al.: IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology, 2006; 131:1153–1163.
68.
WangF, GrahamWV, WangY, WitkowskiED, SchwarzBT, TurnerJR: Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol, 2005; 166:409–419.
69.
WeberCR, RaleighDR, SuL, et al.: Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity. J Biol Chem, 2010; 285:12037–12046.
70.
WeberCR, TurnerJR: Inflammatory bowel disease: Is it really just another break in the wall?. Gut, 2007; 56:6–8.
71.
GrahamWV, HeW, MarchiandoAM, et al.: Intracellular MLCK1 diversion reverses barrier loss to restore mucosal homeostasis. Nat Med, 2019; 25:690–700.
72.
ShenL, WeberCR, RaleighDR, YuD, TurnerJR: Tight junction pore and leak pathways: A dynamic duo. Annu Rev Physiol, 2011; 73:283–309.
73.
MarchiandoAM, ShenL, GrahamWV, et al.: Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol, 2010; 189:111–126.
74.
ClayburghDR, RosenS, WitkowskiED, et al.: A differentiation-dependent splice variant of myosin light chain kinase, MLCK1, regulates epithelial tight junction permeability. J Biol Chem, 2004; 279:55506–55513.
75.
OdenwaldMA, ChoiW, BuckleyA, et al.: ZO-1 interactions with F-actin and occludin direct epithelial polarization and single lumen specification in 3D culture. J Cell Sci, 2017; 130:243–259.
76.
SuL, ShenL, ClayburghDR, et al.: Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology, 2009; 136:551–563.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
